CDRH - Premarket Notification (PMN or 510(k)) for 1999 November 1999 Listings WORLDWIDE MEDICAL TECHNOLOGIES SEEDING SPACERS

WORLDWIDE MEDICAL TECHNOLOGIES SEEDING SPACERS

Decision Date: November 5, 1999 Received: April 19, 1999

Decision Date: November 3, 1999	Received. April 19, 1999		
	WORLDWIDE MEDICAL TECHNOLOGIES, INC.		
Applicant	426 MAIN ST. NORTH		
	P.O. BOX 505		
	WOODBURY CT 067980505		
Contact	GARY A LAMOUREUX		
510(k) Number	K991344 Summary in PDF		
Regulation Number	892.5730		
Decision	Substantially Equivalent (SE)		
Statement/Summary	Statement Only		
Classification Advisory Committ	ee Radiology		
Review Advisory Committee	Radiology		
Product Code	SOURCE, BRACHYTHERAPY, RADIONUCLIDE (KXK)		
Туре	TRADITIONAL		
Third Party Review	No		
Expedited Review	No		





NOV - 5 1999

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Gary A. Lamoureux Worldwide Medical Technologies 426 Main Street, North Woodbury, CT 06798

Dear Mr. Lamoureux:

Re: K991344

Worldwide Medical Technologies

Seeding Spacers
Dated: August 13, 1999
Received: August 16, 1999
Product Code: 90 KXK
Regulatory Class: II (two)

21.CFR 892.5730

We have reviewed your Section 510(k) notification of Intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation your night have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

The state of the s

This lett i will allow you in thep'r in which ing your device as departised in your bridly production notice on the plant. The plant of crims infinitely whence of poor device to a toping appropriate models as when invanishing a term of the product to a charket.

fryon define conditionations from the residual of arranging regulation (21 CFR Post 801 and additionally 800 co using \$100 for 10 using \$1





NOV - 5 1999

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Gary A. Lamoureux Worldwide Medical Technologies 426 Main Street, North Woodbury, CT 06798

Dear Mr. Lamoureux:

Re: K991344

Worldwide Medical Technologies

Seeding Spacers
Dated: August 13, 1999
Received: August 16, 1999
Product Code: 90 KXK
Regulatory Class: II (two)

21.CFR 892.5730

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

CAPT Daniel G. Schultz, M.D.

Acting Director, Division of Reproductive, Abdominal, Ear, Nose and Throat,

and Radiological Devices Office of Device Evaluation Center for Devices and

Radiological Health

510(k) Number (if known):	K99	1344
Device Name: Worldwide l	Medical Technologi	es Seeding Spacers
Indications For Use:		
between radionuclide seeds	during the introduces. The anatomical	Spacers intended use is to provide space tion of radionuclide seeds into the body site is typically the transperineal approach the prostate.
(PLEASE DO NOT WRITE	BELOW THIS LINE-CO	ONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence	of CDRH, Office	of Device Evaluation (ODE)
Prescription Use	OR	Over-The-Counter Use
	ĺ	(Optional Format 1-2-96)
	(Division Sign-Off) Division of Reproduct and Radiological Dev	tive, Abdominal, ENT,
		791344
	EXHIB	i i i